Lipophilic calcium antagonists in antiatherosclerotic therapy.
- Published in:
- Current Atherosclerosis Reports, 2000, v. 2, n. 1, p. 76, doi. 10.1007/s11883-000-0098-9
- By:
- Publication type:
- Article
Works matching IS 15233804 AND DT 2000 AND VI 2 AND IP 1
Results: 13
1
2
Complete and selective estrogenic effects on lipids and cardiovascular disease.
- Published in:
- Current Atherosclerosis Reports, 2000, v. 2, n. 1, p. 72, doi. 10.1007/s11883-000-0097-x
- By:
- Publication type:
- Article
3
Niacin dosing: Relationship to benefits and adverse effects.
- Published in:
- Current Atherosclerosis Reports, 2000, v. 2, n. 1, p. 64, doi. 10.1007/s11883-000-0096-y
- By:
- Publication type:
- Article
4
Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol.
- Published in:
- Current Atherosclerosis Reports, 2000, v. 2, n. 1, p. 58, doi. 10.1007/s11883-000-0095-z
- By:
- Publication type:
- Article
5
Probucol.
- Published in:
- Current Atherosclerosis Reports, 2000, v. 2, n. 1, p. 47, doi. 10.1007/s11883-000-0094-0
- By:
- Publication type:
- Article
6
Mechanism of action of niacin on lipoprotein metabolism.
- Published in:
- Current Atherosclerosis Reports, 2000, v. 2, n. 1, p. 36, doi. 10.1007/s11883-000-0093-1
- By:
- Publication type:
- Article
7
Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk.
- Published in:
- Current Atherosclerosis Reports, 2000, v. 2, n. 1, p. 29, doi. 10.1007/s11883-000-0092-2
- By:
- Publication type:
- Article
8
Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins?
- Published in:
- Current Atherosclerosis Reports, 2000, v. 2, n. 1, p. 20, doi. 10.1007/s11883-000-0091-3
- By:
- Publication type:
- Article
9
Does differing metabolism by cytochrome P450 have clinical importance?
- Published in:
- Current Atherosclerosis Reports, 2000, v. 2, n. 1, p. 14, doi. 10.1007/s11883-000-0090-4
- By:
- Publication type:
- Article
10
Lipid modulation and atherosclerotic events: Extending the clinical spectrum with fibrates and statins.
- Published in:
- Current Atherosclerosis Reports, 2000, v. 2, n. 1, p. 11, doi. 10.1007/s11883-000-0089-x
- By:
- Publication type:
- Article
11
Web alert.
- Published in:
- Current Atherosclerosis Reports, 2000, v. 2, n. 1, p. 5, doi. 10.1007/s11883-000-0087-z
- By:
- Publication type:
- Article
12
Poor compliance: The hidden risk factor.
- Published in:
- Current Atherosclerosis Reports, 2000, v. 2, n. 1, p. 1, doi. 10.1007/s11883-000-0086-0
- By:
- Publication type:
- Article
13
Literature alert.
- Published in:
- Current Atherosclerosis Reports, 2000, v. 2, n. 1, p. 7, doi. 10.1007/s11883-000-0088-y
- By:
- Publication type:
- Article